Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Demystifying the Delivery and Adverse Event Management of Bispecific Antibodies in the Community Setting

Rifeta Kajdic Hodzic, Amitkumar N. Mehta, Jean L. Koff, Elizabeth Budde, Srinivas Devarakonda, Donald C Moore, Joshua Brody, Bradley Wuthrich, Robert Mancini, Cassie Martin, Christina Mangir, Allison Harvey, Elana Plotkin, Molly Kisiel, Ashley Lile, Nicole A Colwell

Blood (2024) 144 (Supplement 1): 2289.

https://doi.org/10.1182/blood-2024-208639

Published: 2024

Journal Articles

Fixed-Duration Epcoritamab + R-CHOP Induces High Complete Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Withhigh-Risk Features: Long-Term Results from the Epcore NHL-2 Trial

Lorenzo Falchi, Fritz Offner, Sven de Vos, Joshua Brody, Raul Cordoba, Kim Linton, Sylvia Snauwaert, Michael Roost Clausen, Toshihiko Oki, Andrew J. Steele, Yi Hao, Kimberly G. Archer, Ali Rana, David Belada

Blood (2024) 144 (Supplement 1): 581.

https://doi.org/10.1182/blood-2024-198023

Published: 2024

Journal Articles

Prevention of Antigen Escape By Modulation of Off-Target Tumor Killing in T Cells

Ivan Odak, Lennart Riemann, Samir Parekh, Joshua Brody

Blood (2024) 144 (Supplement 1): 332.

https://doi.org/10.1182/blood-2024-212011

Published: 2024

Journal Articles

Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study

Blood (2024) 144 (Supplement 1): 865.

https://doi.org/10.1182/blood-2024-194333

Published: 2024

Journal Articles

Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study

Blood (2024) 144 (Supplement 1): 111.

https://doi.org/10.1182/blood-2024-199330

Published: 2024

Journal Articles

Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial

Lori A. Leslie, Chan Y. Cheah, Franck Morschhauser, Justin M. Darrah, Joshua Brody, David Belada, Juraj Duras, Joost S.P. Vermaat, Gerardo Musuraca, Kojo Osei-Bonsu, Yi Hao, Kimberly G. Archer, Monica Wielgos-Bonvallet, Ali Rana, Yasmin H. Karimi

Blood (2024) 144 (Supplement 1): 3106.

https://doi.org/10.1182/blood-2024-199652

Published: 2024

Journal Articles

Fixed-Duration Epcoritamab in Combination with Bendamustine + Rituximab for First-Line Treatment of Follicular Lymphoma: Initial Results from Epcore NHL-2 Arm 3

Joshua Brody, Lorenzo Falchi, Umberto Vitolo, Marcel Nijland, Fritz Offner, Sylvia Snauwaert, Poliana Patah, Jennifer Marek, Christopher Morehouse, Andrew J. Steele, Yi Hao, Daniela Hoehn, Kim Linton

Blood (2024) 144 (Supplement 1): 1627.

https://doi.org/10.1182/blood-2024-200369

Published: 2024

Journal Articles

Odronextamab Monotherapy in Previously Untreated Patients with High-Risk Follicular Lymphoma (FL): Results of the Safety Lead-in of the Phase 3 Olympia-1 Study

Elizabeth Brem, Wojciech Jurczak, David Belada, Jaime Perez de Oteyza, Aranzazu Alonso Alonso, Fevzi Altuntas, Michał Kwiatek, Joshua Brody, Ernesto Perez Persona, Mustafa Yenerel, Monica Tani, Jingxian Cai, Priya Deshpande, Saleem Shariff, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, Ashish Risal, Ruemu Birhiray

Blood (2024) 144 (Supplement 1): 4411.

https://doi.org/10.1182/blood-2024-200080

Published: 2024

Journal Articles

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Blood (2024) 143 (16): 1565–1575.

https://doi.org/10.1182/blood.2023022432

Published: 2024

Journal Articles

Dexamethasone is Associated with a Lower Incidence and Severity of Cytokine Release Syndrome Compared with Other Corticosteroid Regimens When Given as Premedication for Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Lorenzo Falchi, Carmelo Carlo-Stella, Franck Morschhauser, Michael Dickinson, Emmanuel Bachy, Guillaume Cartron, Cyrus Khan, Monica Tani, Joaquin Martinez-Lopez, Nancy L. Bartlett, Antonio Salar, Joshua Brody, Sirpa Leppä, Aurelien Berthier, Martine Kallemeijn, James Relf, Saibah Chohan, Linda Lundberg, Martin Hutchings

Blood (2023) 142 (Supplement 1): 3130.

https://doi.org/10.1182/blood-2023-173949

Published: 2023

Journal Articles

Epcoritamab SC + R-Mini-CHOP Leads to High Complete Metabolic Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: First Disclosure from Arm 8 of the Epcore NHL-2 Trial

Joost S.P Vermaat, Joshua Brody, Juraj Ďuraš, Yasmin H. Karimi, Chan Y. Cheah, Justin M. Darrah, Gerardo Musuraca, Franck Morschhauser, Daniela Hoehn, Ali Rana, Yaou Song, Pegah Jafarinasabian, David Belada

Blood (2023) 142 (Supplement 1): 4457.

https://doi.org/10.1182/blood-2023-180935

Published: 2023

Journal Articles

Epcoritamab SC + GemOx Leads to High Complete Metabolic Response Rates in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Stem Cell Transplant: Updated Results from Epcore NHL-2

Joshua Brody, Judit Mészáros Joergensen, David Belada, Regis T. Costello, Marek Trněný, Umberto Vitolo, David Lewis, Yasmin H. Karimi, Anna Maria Sureda Balari, Marc André, Björn E. Wahlin, Pieternella Lugtenburg, Faith Galderisi, Aqeel Abbas, Yaou Song, Malene Risum, Raul Cordoba

Blood (2023) 142 (Supplement 1): 3092.

https://doi.org/10.1182/blood-2023-180246

Published: 2023

Journal Articles

CNS Prophylaxis Among Patients with HIV-Associated Diffuse Large B-Cell Lymphoma - a Single Center Retrospective Study

Orrin Pail, Christina Darwish, Joshua Brody, Theodora Anagnostou

Blood (2023) 142 (Supplement 1): 6287.

https://doi.org/10.1182/blood-2023-174846

Published: 2023

Journal Articles

Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume

Blood (2023) 142 (Supplement 1): 433.

https://doi.org/10.1182/blood-2023-173951

Published: 2023

Journal Articles

Resistance to CD19 Immunotherapy in B-Cell ALL Is Associated with Loss of CD19 and CD22 and an Enhanced Vulnerability to B Cell Receptor Signaling Inhibition

Blood (2022) 140 (Supplement 1): 3480–3482.

https://doi.org/10.1182/blood-2022-169102

Published: 2022

Journal Articles

Subcutaneous Epcoritamab in Novel Combinations with Antineoplastic Agents Among Patients with B-Cell Non-Hodgkin Lymphoma in a Phase 1b/2, Multicenter, Open-Label Study: Assessing Safety, Tolerability, and Preliminary Efficacy (EPCORE NHL-5)

Laurie H. Sehn, Johannes Duell, Irit Avivi, Joshua Brody, Dok Hyun Yoon, Brian Elliot, Satya R. Siddani, Yang Bai, Apurvasena Parikh, Mostafa M. Seliem, Minh Dinh, Alan P. Skarbnik

Blood (2022) 140 (Supplement 1): 12108–12109.

https://doi.org/10.1182/blood-2022-157596

Published: 2022

Journal Articles

Relapse Is Uncommon in Patients with Large B-Cell Lymphoma Who Are in Complete Remission at the End of Fixed-Course Glofitamab Treatment

Blood (2022) 140 (Supplement 1): 1062–1064.

https://doi.org/10.1182/blood-2022-157554

Published: 2022

Journal Articles

Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R 2 ) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial

Blood (2022) 140 (Supplement 1): 1471–1473.

https://doi.org/10.1182/blood-2022-158232

Published: 2022

Journal Articles

CD229 CAR T Cell Therapy for the Treatment of Relapsed B Cell Lymphoma

Michael Olson, Tim Luetkens, Fiorella Iglesias, Sabarinath Radhakrishnan, Jennie Y. Law, Stephanie Avila, Erica Vander Mause, Nicola J Camp, Erin Morales, Aaron P. Rapoport, Saurabh Dahiya, Joshua Brody, Alana Welm, Djordje Atanackovic

Blood (2021) 138 (Supplement 1): 2800.

https://doi.org/10.1182/blood-2021-154503

Published: 2021

Journal Articles

Subcutaneous Epcoritamab in Combination with R-CHOP in Patients with Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma: Preliminary Results from a Phase 1/2 Trial

David Belada, Jacob Haaber Christensen, Kristina Drott, Sylvia Snauwaert, Joshua Brody, Mayur Narkhede, Fritz Offner, Brian Elliot, Tracy Liu, Mariana Cota Stirner, Aqeel Abbas, Lorenzo Falchi, Michael Roost Clausen

Blood (2021) 138 (Supplement 1): 1413.

https://doi.org/10.1182/blood-2021-146569

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Demystifying the Delivery and Adverse Event Management of Bispecific Antibodies in the Community Setting

Fixed-Duration Epcoritamab + R-CHOP Induces High Complete Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Withhigh-Risk Features: Long-Term Results from the Epcore NHL-2 Trial

Prevention of Antigen Escape By Modulation of Off-Target Tumor Killing in T Cells

Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study

Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study

Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial

Fixed-Duration Epcoritamab in Combination with Bendamustine + Rituximab for First-Line Treatment of Follicular Lymphoma: Initial Results from Epcore NHL-2 Arm 3

Odronextamab Monotherapy in Previously Untreated Patients with High-Risk Follicular Lymphoma (FL): Results of the Safety Lead-in of the Phase 3 Olympia-1 Study

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Dexamethasone is Associated with a Lower Incidence and Severity of Cytokine Release Syndrome Compared with Other Corticosteroid Regimens When Given as Premedication for Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Epcoritamab SC + R-Mini-CHOP Leads to High Complete Metabolic Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: First Disclosure from Arm 8 of the Epcore NHL-2 Trial

Epcoritamab SC + GemOx Leads to High Complete Metabolic Response Rates in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Stem Cell Transplant: Updated Results from Epcore NHL-2

CNS Prophylaxis Among Patients with HIV-Associated Diffuse Large B-Cell Lymphoma - a Single Center Retrospective Study

Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume

Resistance to CD19 Immunotherapy in B-Cell ALL Is Associated with Loss of CD19 and CD22 and an Enhanced Vulnerability to B Cell Receptor Signaling Inhibition

Subcutaneous Epcoritamab in Novel Combinations with Antineoplastic Agents Among Patients with B-Cell Non-Hodgkin Lymphoma in a Phase 1b/2, Multicenter, Open-Label Study: Assessing Safety, Tolerability, and Preliminary Efficacy (EPCORE NHL-5)

Relapse Is Uncommon in Patients with Large B-Cell Lymphoma Who Are in Complete Remission at the End of Fixed-Course Glofitamab Treatment

Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R 2 ) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial

CD229 CAR T Cell Therapy for the Treatment of Relapsed B Cell Lymphoma

Subcutaneous Epcoritamab in Combination with R-CHOP in Patients with Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma: Preliminary Results from a Phase 1/2 Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only